2001 Newbery Medal winner: A conversation with Richard Peck.
- Published in:
- 2001
- By:
- Publication type:
- Interview
Works matching Richard Peck
Results: 73
1
2
A Long Way from Chicago: A Novel in Stories By Richard Peck.
- Published in:
- 2011
- By:
- Publication type:
- Book Review
3
A Review of:“TECHNOLOGY, ECONOMIC GROWTH AND PUBLIC POLICY” By Richard Nelson, Merton Peck, Edward Kalachek Rand and Brookings Institution, Washington, D. C. 1967 228pp.$6.00.
- Published in:
- Engineering Economist, 1968, v. 13, n. 3, p. 191, doi. 10.1080/00137916808928780
- By:
- Publication type:
- Article
4
Richard Peck: A Spellbinding Storyteller.
- Published in:
- 2008
- By:
- Publication type:
- Book Review
5
The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers.
- Published in:
- British Journal of Clinical Pharmacology, 1998, v. 46, n. 5, p. 433, doi. 10.1046/j.1365-2125.1998.00809.x
- By:
- Publication type:
- Article
6
Book reviews.
- Published in:
- 1995
- By:
- Publication type:
- Book Review
7
Condemned to Choose, But What? Existentialism in Selected Works by Fugard, Brink, and Gordimer.
- Published in:
- 1992
- By:
- Publication type:
- Literary Criticism
8
HERMITS AND SAVIORS, OSAGYEFOS AND HEALERS: ARTISTS AND INTELLECTUALS IN THE WORKS OF NGŨGĨ AND ARMAH.
- Published in:
- 1989
- By:
- Publication type:
- Literary Criticism
9
Artificial intelligence assessment of the potential of tocilizumab along with corticosteroids therapy for the management of COVID-19 evoked acute respiratory distress syndrome.
- Published in:
- PLoS ONE, 2023, v. 18, n. 2, p. 1, doi. 10.1371/journal.pone.0280677
- By:
- Publication type:
- Article
10
Development and application of neonatal physiology‐based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainment.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2024, v. 13, n. 3, p. 464, doi. 10.1002/psp4.13097
- By:
- Publication type:
- Article
11
Synthetic Model Combination: A new machine‐learning method for pharmacometric model ensembling.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2023, v. 12, n. 7, p. 953, doi. 10.1002/psp4.12965
- By:
- Publication type:
- Article
12
Model enhanced reinforcement learning to enable precision dosing: A theoretical case study with dosing of propofol.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2022, v. 11, n. 11, p. 1497, doi. 10.1002/psp4.12858
- By:
- Publication type:
- Article
13
Models and Machines: How Deep Learning Will Take Clinical Pharmacology to the Next Level.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2019, v. 8, n. 3, p. 131, doi. 10.1002/psp4.12377
- By:
- Publication type:
- Article
14
The effects of cyclosporin A on the chicken immune system.
- Published in:
- European Journal of Immunology, 1982, v. 12, n. 10, p. 867, doi. 10.1002/eji.1830121013
- By:
- Publication type:
- Article
15
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of RO5068760, an MEK Inhibitor, in Healthy Volunteers: Assessment of Target Suppression.
- Published in:
- Journal of Clinical Pharmacology, 2010, v. 50, n. 12, p. 1397, doi. 10.1177/0091270010361254
- By:
- Publication type:
- Article
16
POWER AND LINEAR INCOME TAXES: AN EXAMPLE.
- Published in:
- Econometrica, 1986, v. 54, n. 1, p. 87, doi. 10.2307/1914158
- By:
- Publication type:
- Article
17
TIME PREFERENCE AND UNCERTAIN LIFETIME.
- Published in:
- American Economist, 1986, v. 30, n. 2, doi. 10.1177/056943458603000206
- By:
- Publication type:
- Article
18
Use of quantitative clinical pharmacology to improve early clinical development success in neurodegenerative diseases.
- Published in:
- Expert Review of Clinical Pharmacology, 2018, v. 11, n. 8, p. 789, doi. 10.1080/17512433.2018.1501555
- By:
- Publication type:
- Article
19
Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis.
- Published in:
- Expert Review of Clinical Pharmacology, 2011, v. 4, n. 5, p. 539, doi. 10.1586/ecp.11.33
- By:
- Publication type:
- Article
20
Implications of food subsistence for monetary policy and inflation.
- Published in:
- Oxford Economic Papers, 2016, v. 68, n. 3, p. 782, doi. 10.1093/oep/gpw017
- By:
- Publication type:
- Article
21
The pharmacodynamics and pharmacokinetics of the 5HT<sub>1B/1D</sub>-agonist zolmitriptan in healthy young and elderly men and women<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 1998, v. 63, n. 3, p. 342, doi. 10.1016/S0009-9236(98)90166-7
- By:
- Publication type:
- Article
22
Inhibition of dihydropyrimidine dehydrogenase by 5-propynyluracil, a metabolite of the anti-varicella zoster virus agent netivudine<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 1996, v. 59, n. 1, p. 22, doi. 10.1016/S0009-9236(96)90020-X
- By:
- Publication type:
- Article
23
Vital communities: the promise of 'New Urbanism' in seniors housing.
- Published in:
- Journal on Active Aging, 2010, v. 9, n. 2, p. 78
- By:
- Publication type:
- Article
24
Neuropeptides Modulating Macrophage Function.
- Published in:
- Annals of the New York Academy of Sciences, 1987, v. 496, n. 1, p. 264, doi. 10.1111/j.1749-6632.1987.tb35774.x
- By:
- Publication type:
- Article
25
The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90).
- Published in:
- British Journal of Clinical Pharmacology, 1997, v. 44, n. 6, p. 595, doi. 10.1046/j.1365-2125.1997.t01-1-00632.x
- By:
- Publication type:
- Article
26
The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers.
- Published in:
- British Journal of Clinical Pharmacology, 1997, v. 43, n. 3, p. 273, doi. 10.1046/j.1365-2125.1997.00547.x
- By:
- Publication type:
- Article
27
Recent Advances Addressing the Challenges of Precision Dosing.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 116, n. 3, p. 527, doi. 10.1002/cpt.3365
- By:
- Publication type:
- Article
28
Beyond Population‐Level Targets for Drug Concentrations: Precision Dosing Needs Individual‐Level Targets that Include Superior Biomarkers of Drug Responses.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 116, n. 3, p. 602, doi. 10.1002/cpt.3197
- By:
- Publication type:
- Article
29
Using Machine Learning to Individualize Treatment Effect Estimation: Challenges and Opportunities.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 4, p. 710, doi. 10.1002/cpt.3159
- By:
- Publication type:
- Article
30
Ensuring Transparency and Quality of Clinical Trial Reporting in Clinical Pharmacology & Therapeutics: Prospective Trial Registration and Compliance with Reporting Guidelines Are Required for all Clinical Trials.
- Published in:
- Clinical Pharmacology & Therapeutics, 2023, v. 114, n. 6, p. 1153, doi. 10.1002/cpt.3070
- By:
- Publication type:
- Article
31
Digital Therapeutics as a New Therapeutic Modality: A Review from the Perspective of Clinical Pharmacology.
- Published in:
- Clinical Pharmacology & Therapeutics, 2023, v. 114, n. 3, p. 578, doi. 10.1002/cpt.2989
- By:
- Publication type:
- Article
32
BIA 10‐2474: Some Lessons are Clear but Important Questions Remain Unanswered.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 2, p. 343, doi. 10.1002/cpt.2495
- By:
- Publication type:
- Article
33
Response to "Personalized Dosing = Approved Wide Dose Ranges + Dose Titration".
- Published in:
- Clinical Pharmacology & Therapeutics, 2021, v. 109, n. 3, p. 568, doi. 10.1002/cpt.1995
- By:
- Publication type:
- Article
34
Precision Dosing: The Clinical Pharmacology of Goldilocks.
- Published in:
- Clinical Pharmacology & Therapeutics, 2021, v. 109, n. 1, p. 11, doi. 10.1002/cpt.2112
- By:
- Publication type:
- Article
35
Precision Dosing: An Industry Perspective.
- Published in:
- Clinical Pharmacology & Therapeutics, 2021, v. 109, n. 1, p. 47, doi. 10.1002/cpt.2064
- By:
- Publication type:
- Article
36
Drug Dosing Recommendations for All Patients: A Roadmap for Change.
- Published in:
- Clinical Pharmacology & Therapeutics, 2021, v. 109, n. 1, p. 65, doi. 10.1002/cpt.1923
- By:
- Publication type:
- Article
37
A Real‐World Evidence Framework for Optimizing Dosing in All Patients With COVID‐19.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 5, p. 921, doi. 10.1002/cpt.1922
- By:
- Publication type:
- Article
38
Data Science in Clinical Pharmacology and Drug Development for Improving Health Outcomes in Patients.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 4, p. 683, doi. 10.1002/cpt.1803
- By:
- Publication type:
- Article
39
Model‐Informed Artificial Intelligence: Reinforcement Learning for Precision Dosing.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 4, p. 853, doi. 10.1002/cpt.1777
- By:
- Publication type:
- Article
40
Organs‐on‐Chips in Clinical Pharmacology: Putting the Patient Into the Center of Treatment Selection and Drug Development.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 1, p. 181, doi. 10.1002/cpt.1688
- By:
- Publication type:
- Article
41
Development and Implementation of Electronic Health Record–Integrated Model‐Informed Clinical Decision Support Tools for the Precision Dosing of Drugs.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 1, p. 129, doi. 10.1002/cpt.1679
- By:
- Publication type:
- Article
42
A Framework Proposal to Follow‐Up on Preclinical Convulsive Signals of a New Molecular Entity in First‐in‐Human Studies Using Electroencephalographic Monitoring.
- Published in:
- Clinical Pharmacology & Therapeutics, 2019, v. 106, n. 5, p. 968, doi. 10.1002/cpt.1455
- By:
- Publication type:
- Article
43
Strategies in Selecting an Agent for Clinical Trials.
- Published in:
- Annals of the New York Academy of Sciences, 1997, v. 823, n. 1, p. 319, doi. 10.1111/j.1749-6632.1997.tb48406.x
- By:
- Publication type:
- Article
44
Nitrogen Farming in the Mississippi Watershed: A Policy Comparison.
- Published in:
- Journal of Economics (0361-6576), 2011, v. 37, n. 2, p. 1
- By:
- Publication type:
- Article
45
Economic Perspectives on Addiction: Hyperbolic Discounting and Internalities.
- Published in:
- Journal of Economics (0361-6576), 2009, v. 35, n. 2, p. 1
- By:
- Publication type:
- Article
46
Infinitesimal Firms and Increasing Cost Industries.
- Published in:
- Journal of Economic Education, 2001, v. 32, n. 1, p. 41, doi. 10.2307/1183213
- By:
- Publication type:
- Article
47
Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2015, v. 76, n. 3, p. 587, doi. 10.1007/s00280-015-2830-8
- By:
- Publication type:
- Article
48
An Updated Review of Iclaprim: A Potent and Rapidly Bactericidal Antibiotic for the Treatment of Skin and Skin Structure Infections and Nosocomial Pneumonia Caused by Gram-Positive Including Multidrug-Resistant Bacteria.
- Published in:
- Open Forum Infectious Diseases, 2018, v. 5, n. 2, p. N.PAG, doi. 10.1093/ofid/ofy003
- By:
- Publication type:
- Article
49
The Role of Retail Prices and Promotions in Determining Cigarette Brand Market Shares.
- Published in:
- Review of Industrial Organization, 2006, v. 28, n. 3, p. 253, doi. 10.1007/s11151-006-0016-6
- By:
- Publication type:
- Article
50
Beware Wilbur Smith's Gaboon adder: Purple prose, propaganda and politics in South Africa.
- Published in:
- Journal of Contemporary African Studies, 1994, v. 12, n. 2, p. 151, doi. 10.1080/02589009408729555
- By:
- Publication type:
- Article